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HIV/AIDS has caused millions of deaths and untold suffering throughout the world. Although there is no cure, treatment exists that has transformed this disease from an acutely lethal infection into a manageable chronic illness.  However, successfully treating HIV/AIDS requires high levels of adherence to prescribed medications.  Unlike most aspects of antiretroviral treatment, adherence depends on the behavior of the patient, which is influenced by a multitude of factors from every sector of society.  This paper discusses the challenges to treatment adherence within a model country, South Africa.  To highlight the necessity of addressing obstacles to adherence, this paper also investigates the biological consequences resulting from poor adherence.  These consequences are significant for both the individual and humanity as a whole.  Establishing a medical strategy to treat HIV/AIDS is not enough; turning the tides of the HIV/AIDS pandemic will require an understanding of the societal factors affecting adherence as well.
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	Often referred to as the modern plague, the pandemic caused by the Human Immunodeficiency Virus (HIV) is unlike any other biological threat our species has faced.  It is responsible for 2.8 million deaths in a single year and relentless suffering in its 38.6 million present victims (UNAIDS 2006).  HIV subversively undermines our immune system, crippling the physiological defenses designed to protect us from this very type of threat.  But the terrible effects of HIV take time to manifest into Acquired Immune Deficiency Syndrome (AIDS), allowing an unwary host to further spread infection.  There is no vaccine.  There is no cure.  Once HIV/AIDS takes hold within a population, its grave consequences begin to emerge.  The most productive age groups are hardest hit—destabilizing the area’s economy and leaving millions of orphaned children (UNAIDS 2006).  Some regions are so adversely affected by the epidemic that the term ‘undeveloping country’ has been coined to describe nations smothered by HIV/AIDS (Berger 2002).
	A medical crisis as socially complex and far-reaching as the HIV/AIDS pandemic stirs much controversy about what strategy will best forestall disaster.  Epidemiologically, there are two approaches to managing widespread disease—prevention and treatment.  Many public health programs have emphasized prevention measures over treatment provision in developing countries primarily because they are less expensive.  While prevention is absolutely vital in the fight against HIV/AIDS, especially where resources are limited, this uneven focus may have promoted the appallingly inadequate medical care available to the same populations.  International public health authorities Joia Mukherjee and Paul Farmer write,
Prevention of HIV infection is often promoted as the only feasible option in resource poor settings despite the existence of drugs to treat it.  As recently as 2002, experts argued that prevention should take priority over treatment for AIDS in Africa based on cost effectiveness.  However, cost effectiveness analyses fail to take into account the most important reason for implementing widespread HIV treatment—treating sick people (Mukherjee et al. 2003).

It is essential that in the midst of managing a pandemic, we do not get lost in the incomprehensible numbers and remember that, above all, this terrible virus robs people of their lives.  Thanks to the diligent efforts of dedicated scientists, we now have antiretroviral medications to treat HIV/AIDS, granting more years of life to HIV-positive individuals and improving the quality of that time.
Fortunately, access to this critical treatment is expanding throughout the world.  The efforts of governments, non-profit organizations and international funding groups have aided countless people by providing the life-prolonging therapies.  However, we must also realize that the initiation of HIV/AIDS treatment is exactly that, the beginning.  Because HIV/AIDS is a chronic condition, treatment must be maintained for the rest of the patient’s life.  This sustained adherence depends on a multitude of factors, many of which fall outside of the patient’s immediate control.  From economic pressures to cultural misconceptions, patients are confronted by considerable obstacles that could jeopardize their antiretroviral treatment.
Without the proper compliance to prescribed medications, HIV will ultimately prevail within the non-adherent patient.  However, the ramifications of poor adherence are more severe than just poor treatment outcome.  These consequences extend beyond the individual, undermining our ability to treat HIV/AIDS and threatening the world as a whole.  
If adherence is not effectively addressed in parallel with treatment expansion, then “the provision of antiretroviral drugs will produce chaos, not control” (Horton 2000).  This paper explores HIV/AIDS treatment adherence within a model country, South Africa.  It will first set the stage by introducing South Africa and explaining this country’s relevance as a model for an analysis of adherence. Secondly, this paper presents the necessary background information about HIV/AIDS, available treatments and adherence.  The bulk of this paper addresses the societal factors within South Africa that affect a patient’s ability to adhere to his or her medication regimen.  By discussing multiple examples across various sectors of society, this paper aims to illustrate the complexity and diversity of the issues surrounding adherence.  Lastly, this paper examines the biological consequences and public health implications of poor adherence in order to highlight the severity of this challenge.  

South Africa as a Model
	HIV/AIDS has spread across every inhabited continent and infiltrated even the most isolated communities.  However, this deleterious dispersion has been far from uniform.  Sub-Saharan Africa contains only one tenth of the world’s population, but approximately 64% of the world’s HIV-infected population reside in this region as of 2005 (UNAIDS 2006).  Prevalence rates—the percentage of people infected with HIV—in these countries hover between 15-34%.  South Africa’s prevalence rate is estimated at 16.2% (WHO 2005).  Although this value is on the lower side, South Africa differs from its neighbors with higher rates because the prevalence rate in South Africa is increasing (UNAIDS 2006).  Furthermore, an estimated 5.5 million HIV-positive people live within the borders of South Africa—more than any other country in the world (McNeil 2007).  Clearly, South Africa sits securely at the apex of the global HIV/AIDS pandemic.
	In addition to statistics stressing South Africa’s relevance in any discussion of HIV/AIDS, this country is politically, socially and culturally unique.  The current government was installed in 1994 with the dissolution of the racially oppressive apartheid regime.  The new administration adopted one of the most liberal constitutions in the world, including rights to free and universal healthcare, but the political system is still immature and has yet to fulfill many of its early promises (Thompson 2000).  With the fall of apartheid, racial restrictions were removed and South Africa became the multicultural ‘rainbow nation’.  Regretfully, the country is still rife with social inequality even after this transformation.  Moreover, despite the country’s relative wealth, there is tremendous economic disparity present in South Africa.  Like a jumble of assorted jigsaw puzzles, South Africa is characterized by an array of interspersed ethnic and economic groups.  The intersection of first and third worlds under a new democracy, infused with extraordinary cultural diversity, makes South Africa an ideal environment to study the societal factors that affect treatment adherence.  Many of the elements associated with HIV/AIDS treatment anywhere in the world are exaggerated in the context of South Africa, be it by the social environment or the sheer numbers of affected people.

Background on HIV/AIDS and Antiretroviral Treatment
The Biological Players
HIV stands for Human Immunodeficiency Virus; reversing this wording helps illustrate its definition—it is a virus that specifically targets and devastates the immune system in humans.  As with all viruses, HIV is a particle many times smaller than a cell, which contains genetic material protected by a protein envelope.  Once HIV enters the body, it seeks out its target—our immune system.  The human immune system is a network of vessels and specialized junctions through which cells called leukocytes (white blood cells) monitor physiological conditions and share information about sites of damage and foreign invasion.  These leukocytes come in many forms so they can successfully identify and manage a variety of physiological problems.  Most relevantly, HIV seeks out helper T-cells, a certain type of leukocyte that detects foreign antigens and communicates the threat throughout the immune system.  HIV infects helper T-cells, among a few other types of cells, because they exhibit surface proteins called CD4-receptors which, under normal circumstances, lets them recognize certain types of pathogens (Weeks and Alcamo 2006) p.72).  However, after infection, the CD4-receptor acts as a lock to which HIV has the key, allowing the virus into the cell.
Inside the host cell, HIV’s protective capsule dissolves, releasing the ribonucleic acid (RNA) based genetic material and viral enzymes.  Viral reverse transcriptase (RT) transcribes the RNA chain into deoxyribonucleic acid (DNA)—the genetic material found in human cell nuclei.  Normal cellular processing transcribes DNA into RNA copies which are then used to construct proteins.  So RT’s synthesis of DNA from RNA is backward, earning HIV its classification as a ‘retrovirus’.  The new viral DNA strand migrates to the nucleus of the host cell where another viral enzyme, integrase, incorporates it into the host genome.  After this stage, HIV is permanently assimilated into the host cell and referred to as a provirus where it can lie dormant for many years.  The eventual stimulation of the HIV provirus produces new RNA strands which manufacture viral proteins by hijacking the host cell’s biological machinery and resources.  Lastly, a third viral enzyme, protease, cleaves the proteins into active forms.  These components congregate at the cell surface and bud off as new HIV particles, continuing to spread the infection.
While the initial phase of the disease manifests itself with symptoms similar to the common cold, the HIV infection steadily grows in strength and severity.  Eventually, it incapacitates the majority of CD4-positive T-cells (CD4) which are crucial to the function of the immune system as a whole.  Proper diagnosis depends on many factors, but when an individual reaches a CD4 count lower than 200 cells/µL of blood—a significant drop from normal levels of about 1000 cells/µL—they are generally diagnosed with Acquired Immunodeficiency Syndrome (AIDS) (Centers for Disease Control and Prevention 1992). The period from initial infection to AIDS take between 10-12 years on average.  Clinically, the progression of HIV/AIDS is monitored by laboratory tests which report the concentration of HIV RNA—called viral load (VL)—and the CD4 count.  Aside from opportunistic infections, the direct consequences of AIDS often include chronic diarrhea, wasting syndrome, prolonged fever, dementia and a type of cancer called Karposi’s sarcoma (Weeks and Alcamo 2006) p81).  
However, the degradation of the immune system does not usually cause death but instead renders the body incapable of fighting off normally benign pathogens.  Opportunistic diseases result from organisms across a broad range, including: protozoa, fungi, bacteria and other viruses, which exploit the body’s shattered defenses.  AIDS-related illnesses affect multiple regions of the body such as the pulmonary, gastro-intestinal and neurological systems.  The types of opportunistic diseases that are most prevalent in a population depend on the region; for example, tuberculosis has an extremely high incidence rate among HIV-positive individuals in many African countries whereas it is relatively rare in the US.  Consideration of these secondary infections is vital in overall treatment, because these opportunistic diseases directly kill individuals with AIDS.

Antiretroviral Treatments
Despite the discouraging outlook of HIV/AIDS progression, hope lies in the fact that viable treatments have been developed over the last two decades to curb the lethal course of this illness.  The first antiretroviral drug approved by the FDA in 1987 was AZT (zidovudine), originally designed to treat cancer.  This drug was successful in that it slowed disease progression and instilled optimism in the HIV/AIDS-affected community.  Regretfully, it was later shown that treatment with AZT did not increase overall survival rate (Institute of Medicine 2005a) p43).  This outcome, which will be explained below, spurred drug development in several different directions ultimately producing four distinct classes of drugs.
The first were nucleoside reverse transcriptase inhibitors (NRTI), AZT included, which stop the process of elongation performed by the viral enzyme RT.  As mentioned earlier, without functional RT, viral RNA cannot be converted to DNA, stopping HIV in its tracks.  To produce DNA, this enzyme strings nucleosides, the building blocks of genetic material, together in a sequence that complements a template strand of RNA.  NRTIs work by resembling a nucleoside in every aspect except the portion that couples with the next nucleoside in sequence.  If RT incorporates a NRTI into its DNA copy the reaction cannot continue, which leaves the enzyme blocked and the DNA strand unfinished.  If RT were a machine that manufactures a long metal chain by connecting the links one at a time, administering a NRTI is essentially throwing scrap metal on the conveyer belt until the machine clogs and breaks down.  A second group of medication targets RT with a different approach.  Non-nucleoside reverse transcriptase inhibitors (NNRTIs) directly react with the RT enzyme and inhibits it’s activity.  In the same analogy, NNRTIs take a sledgehammer to the chain-making-machine—the overall outcome is the same.
Researchers did not stop at RT when developing HIV-enzyme inhibiting drugs; protease was also a target for drug development.  Substances that fit into the active site of this enzyme are called protease inhibitors (PI) and prevent new viral proteins from being cleaved into viable forms.  This slows the progress of HIV infection because new viruses cannot effectively form and bud off from the host cell without the appropriate proteins. The last class of antiretroviral drugs, fusion inhibitors (FI), halts HIV before it can enter and infect host cells.  This drug became available for clinical use in 2003, but is reserved for patients in which the other treatments have failed (Institute of Medicine 2005b). FI works by blocking the interaction between HIV and the CD4-receptors of the host cells.  FIs carry promise because they could potentially prevent HIV infection even after system exposure.




Despite the many successes, none of the previously mentioned treatments are a cure.  Once an individual becomes infected with HIV, they must manage the disease and associated therapy for the rest of their life.  Successful ART is defined as “maximal and durable suppression of viral load, restoration and preservation of immunologic function, improvement of quality of life, and reduction of HIV-related morbidity and mortality” (Dybul et al. 2002).  This positive outcome is possible with ART, but it requires strict and accurate adherence to the prescribed treatment.  
Optimal adherence has been defined based on the virologic, immune, and clinical outcomes of patients whose adherence was measured during longitudinal studies.  For PI-based ART regimens, (Paterson et al. 2000) describes optimal outcome in patients who take ≥95% of the medications prescribed by their physician. Specifically, they showed that there was a significant decrease, from 80% to 50%, in virologic success, or reduction of a patient’s VL, with patients who had <95% adherence.  Although this sharp drop in positive virologic outcomes was not shown in NNRTI-based regimens, there was still a linear relationship between adherence and virologic outcome (Nachega et al. 2007).  This suggests that as the patient’s adherence level to NNRTI-based regimens increases, there is a respective increase toward a positive outcome continuing up to perfect, 100%, adherence.  Therefore, the majority of literature defines the cut-off for optimal adherence to either PI- or NNRTI-based regimens between the relatively high levels of ≥90-95%.  Because of this important adherence threshold, publications addressing adherence most often report the percentage of patients with optimal adherence instead of just the average adherence rate. 
With such a large pill load, maintaining such exceptional levels of adherence requires precise and rigorous treatment management.  A South African patient taking the first-line ARV regimen must take five pills in 24 hours. Compared to patient’s that can afford the combination pills that include several drugs within one pill, this is a very high frequency.  In order to remain >95% adherent to ART, a patient could miss no more than seven out of the 150 pills the patient takes per month, and they must be taken at the prescribed time.  Moreover, like any other substance in the bloodstream, ARVs are metabolized and excreted as time passes.  In order to keep blood concentrations of the viral-suppressing drugs at effective levels, it is also imperative that patients take their medications within an hour of the designated time (Bartlett 2005).  When patients do not accurately adhere to their regimen schedule and take their drugs too late or too early, blood concentrations can drop below the level necessary to suppress HIV or rise to levels that are hazardous to the patient.

The Adherence Situation in South Africa
On September 3, 2003, headlines of the New York Times read, ‘Africans Outdo US Patients in Following AIDS Therapy’ (McNeil 2003).  This optimistic pronouncement came as a response to several African studies on adherence rates, including one from South Africa (Orrell et al. 2003).  These quantitative studies reported higher—hovering around 90%—averages of ARV adherence compared to the respective data from the US, which reported average adherence around 70% (McNeil 2003).  A more recent journal article analyzed 58 adherence studies across North America and sub-Saharan Africa and reported a similar disparity.  (Mills et al. 2006b) determined that an average of 55% of patients in the US and 77% of the patients in Africa achieved optimal adherence levels.  These remarkable conclusions are reassuring and rebuff pessimistic sentiments that predicted ‘doomsday’ scenarios for the widespread provision of ART in sub-Saharan Africa (Harries et al. 2001; Popp and Fisher 2002).  However, as will be addressed below, many concerns about ART in Africa and potential negative consequences are worthy of serious discussion.
Several studies specific to South Africa also showed relatively high percentages of patients with optimal adherence (Table 1).  For all these region-specific studies the average percentage of patients with optimal adherence was 70%, similar to that reported for all of sub-Saharan Africa (Mills et al. 2006b).

Table 1 – Adherence Reports in South Africa
Source	Location	No. of Participants	Method of Assessment	Duration of Study	Percentage of Patients with Optimal Adherence*
(Brown and Friedland 2004)	Durban	50	Self-Report	12wks	76% had ≥100% adherence
(Darder et al. 2004)	Cape Town	192	Self-Report	12mos	88% had ≥95% adherence
(Ferris et al. 2004)	Durban	74	Self-Report	N/A	77% had ≥95% adherence
(Nachega et al. 2004)	Soweto	66	Self-Report	1mo	88% had ≥95% adherence
(Nachega et al. 2006a)	Cape Town	6288	Pharmacy claims	12mos	30% had ≥100% adherence
(Nachega et al. 2007)	Cape Town	2821	Pharmacy claims	2.2yrs	47% had ≥90% adherence
(Orrell et al. 2003)	Cape Town	289	Pill counts and pharmacy refill	48wks	45% had ≥95% adherence
*as defined by individual study
While they show relatively high levels of adherence, none of the studies argue that adherence is not a vital aspect to successful ART and they acknowledge adherence as a complex and socially-intertwined variable.  Mills et al. (2006a) and the authors of almost every included study reiterate, and aim to demonstrate with their data, that prejudice-rooted reservations about ARV adherence in Africa are simply not valid based on the data (Mills et al. 2006a; Nachega et al. 2004; Orrell et al. 2003).  They argue that concerns about adherence should in no way discourage the provision of ART in sub-Saharan Africa, the region hardest by the HIV/AIDS pandemic. 
While this paper agrees with the conclusions of the aforementioned authors and highly value their contention regarding access to ART in sub-Saharan Africa, it must draw attention to the many limitations of adherence studies in order to promote a healthy skepticism when interpreting such impressive headlines as those reported in the New York Times.  Moreover, the following analysis strives to expose and challenge a possible unintended consequence of the previously mentioned studies—a false sense of security about the adherence situation in South Africa that could potentially cause a decline in the awareness, funding, and vigilance required for success in the battle against HIV/AIDS.

The Challenge of Measuring Adherence
The high degrees of adherence necessary for successful ART allude to the importance of accurately and precisely assessing this variable.  However, an array of methods for measuring adherence exist (Table 2).  Each contains distinct advantages and disadvantages including cost, complexity, accuracy, intrusiveness and bias.  There is no gold standard, and the selection of a particular method varies depending on availability and researcher preference.  By analyzing studies measuring adherence, (Gill et al. 2005) found large discrepancies between the different methods used on the same groups. With this information they constructed a relative hierarchy of adherence measurement methods, “with physician assessment and self-report being least accurate, pill counts intermediate, and EDM [electronic drug monitoring] the most accurate surrogate adherence marker”.  The ideal way to measure adherence would be through a program modeled after the tuberculosis control strategy, direct observed treatment short-course (DOTS) which requires a treatment supporter to oversee compliance to the medication regimen for every dose.  DOTS has proved extremely effective at controlling tuberculosis in resource-constrained settings but has yet to be successfully implemented for ART (Liechty and Bangsberg 2003). This hierarchy provides a qualitative comparison between measures useful for discussing the strengths and weaknesses of any adherence study.




Information about clinical outcomes of patients participating in adherence evaluations provides evidence supporting this reservation about the self-reporting method.  The link between high levels of adherence and undetectable viral loads (UDVL) has been established in multiple studies using EDM and DOTS (Chesney et al. 1999; Gill et al. 2005; Paterson et al. 2000).  These studies found UDVL in 78%-85% of their patients with optimal adherence.  In comparison, the data reported by (Brown and Friedland 2004), who used self-report to assess adherence, showed that only 57% of the group claiming 100% adherence achieved UDVL.  Although this negative outcome did not occur in all self-report studies, it illustrates a potential disconnect between self-report and virologic outcome. 
Furthermore, a comparison of the two groups in Table 1, those studies using self-report and those using the more objective pharmacy claims, displays a remarkable pattern.  The self-report studies all present data that places adherence at a very high level, with an average 82% of the patients achieving optimal adherence as defined by the individual study.  However, a dramatically lower percentage is reported by the studies using pharmacy claims.  For these two studies, the average percentage of patients achieving optimal adherence drops to an alarming 40.8%, half the value determined by self-report.  According to these pharmacy claim studies, less than half of the participants are taking their treatment at the level required for ideal treatment outcomes.  This sharp drop between studies, similar in most respects except their assessment methods, supports the notion that bias in self-reporting has a considerable false-positive effect on the adherence studies.
The participant population for adherence studies in resource-constrained settings elicits separate concerns.  First, in a country where ART is restricted to a narrow minority, the individuals who first gain access may “possess greater resources, heightened motivation, and are probably not representative of the larger HIV epidemic” (Bangsberg, Ware and Simoni 2006).  In addition to population bias, there is considerable selection bias in these studies.  Often, the participants were referred to the studies from a hospital specifically because their motivation regarding ART was above average (Orrell et al. 2003).  Furthermore, strict inclusion rules for participants may have selected for patients with a social situation facilitating high adherence.  The Darder et al. (2004) study had substantial inclusion guidelines, as reported by the same New York Times article, 
To qualify for treatment, patients must give up all alcohol and drugs; complete three months of taking a simple antibiotic; be on time for four clinic appointments in a row; reveal to their families that they are H.I.V. positive; and choose a friend who must come to counseling, make sure all pills are taken and report problems to a nurse (McNeil 2003).

Clearly, these stringent guidelines would exclude patients with social conditions and mentalities that predispose them have poor adherence.  Even more blatantly, Orrell et al. (2003) excluded the data of 47 (16%) patients who discontinued ART before the completion of the follow-up.  The unrepresentative character of the available populations as well as inclusion and exclusion biases of these studies greatly limit the applicability of their conclusions to the larger population—especially the disadvantaged, and often ignored, populations whose adherence is of greatest concern.
	Lastly, the environment created by the researchers may also skew the results toward better adherence.  In all of the publications that reported this information, the large majority of participants received ARVs free of charge directly from the study or through some other organization, thus removing any drug-cost-related barrier to adherence.  In several of the listed studies, patients received information and support from dedicated staff, a beneficial environment which is not representative of the widespread healthcare experience in South Africa.  This extra education and attention doubtlessly promoted adherence and again reduces the applicability of these findings to the larger population.  Essentially, these studies removed many of the barriers to the very thing they were attempting to quantify.
	The publication by Orrell et al. (2003) that provoked the New York Times article proclaiming that Africans had trumped their North American counterparts is titled, Adherence is not a barrier to successful antiretroviral therapy in South Africa.  More explicitly, Orrell et al. (2003) and the other research groups have shown that adherence does not have to be a barrier when adequate access to ART is provided, education and support is available, and adverse social conditions are addressed.  The conclusions of the selected researchers are positive, and they inspire optimism that success is possible for long term ART as it becomes available in South Africa.  However, the environment in which these studies were conducted is not representative of that experienced by the vast majority of people in South Africa in need of ART.  




II. SOCIETAL FACTORS AFFECTING ANTIRETROVIRAL ADHERENCE

How Does a Patient’s Environment Affect the Ability to Adhere?
	By no means is this investigation comprehensive; the potential challenges to adherence are as varied as the lives of those patients on ART.  Every patient has his or her own unique experience with ART and the difficulties they face will, in large part, be a product of their individual social situation.  For this reason, patient-related factors, such as forgetfulness, motivation, substance abuse, and psychological illness, will not be examined.  This does not mean that these factors are inconsequential to successful ART; in fact, many studies have shown that they are among the most significant (Chesney 2000; Walsh et al. 2001).  Instead, this paper focuses on broader social concerns that are outside of a patient’s direct control and affect a broad swath of the population on ART in South Africa.  These issues span a diverse spectrum and include health service factors, economic factors, cultural and social factors, and disease and treatment factors.
	Regretfully, there are very few surveys addressing barriers to ARV adherence specific to South Africa.  The majority of these studies also limit their analysis to direct excuses of why a patient missed a dose instead of investigating the larger-scale challenges that an ART patient faces in order to persist with his or her treatment.  For this reason, many of the factors addressed in this paper are speculative but grounded in relevant statistics and the application of findings in other sub-Saharan African countries.

Health Service Factors
The provision of ART is complicated and requires extensive resources and management.  A South African professor of health policy, Helen Schneider, writes, 
Ensuring life-long treatment, accessible and well-functioning health facilities, management of referral relationships, partnerships with non-state actors, monitoring and evaluation, and removing the many barriers to entry and remaining in care, all imply a high level of systems and managerial capacity.  This makes ARVs more complex than many other health care interventions (Schneider et al. 2006).
  




Accessibility of ART Facilities
According to the World Health Organization (WHO), less than 19% of those people in need of ART in South Africa are receiving it in 2005 (WHO 2005).  Unless drastic action is taken, this minimal percentage will only shrink further as the AIDS epidemic approaches its zenith and many more HIV-positive South Africans become desperately ill.  Yet even for the fortunate minority who do receive ART from private institutions, non-governmental organizations (NGOs), or the few ART locations being rolled out in the public sector, accessing the necessary care from these facilities is not without hardship.  A South African patient on ART must make an average of 26.5 visits per year—over twice a month—to his or her clinic for ART (Cleary et al. 2005).  This high frequency of clinic visits to maintain ART would be a burden to anyone, but the inadequate infrastructure of the current healthcare system in South Africa amplifies this constraint.  Limited availability of ART locations creates two obstacles for patients—long distances to travel to receive care and excessive waiting times.
The last census reported that, in 2001, 42.5% of South Africans lived in rural areas whereas the majority of ART sites are associated with larger urbanized clinics or hospitals (United Nations Development Programme 2006).  This disconnect presents a formidable and recurring challenge to ART patients, who must make frequent trips to their ART site for prescriptions and appointments.  A recent report by Tanser et al. (2006), analyzed the accessibility of healthcare facilities for rural South Africans and found that the median travel time to the nearest clinic was 81 minutes, with 65% of residents traveling greater than one hour.  More likely, a patient’s ART would not be located at the nearest clinic and the researcher’s estimation of 170 minutes of travel time to the nearest district hospital may be more representative (Tanser et al. 2006).   Tanser et al. (2006) also found a negative correlation between travel time and clinic usage reporting, “The adjusted odds of a homestead within 30 min of a clinic making use of the clinics were 10 times those of a homestead in the 90-120 min zone” (Tanser, Gijsbertsen and Herbst 2006).  Because consistent clinic attendance for review appointments and pharmacy refills is so critical to adherence, this decrease in usage due to travel time poses a significant barrier.  Supporting this inference, a study in Botswana found that, of those participants reporting that the frequency of required clinic visits as a barrier, 50% attributed this to travel distance (Weiser et al. 2003).  As ART in South Africa begins to scale up and become available to a larger population, this issue will become a greater concern unless decentralization of ART sites accompanies expansion.
In addition to geographical restrictions caused by limited ART locations, the patient burden on these few sites cause an increase in waiting time and a decrease in duration of the actual consultation.  A national survey conducted by the Health Systems Trust in South Africa found, “Among those who went to a public hospital, 63% spent at least two hours waiting to be seen” and “[m]any people, having waited for at least two hours for a consultation find that the actual visit lasts five minutes or shorter” (Hirschowitz et al. 1995).  This considerable imbalance between waiting time and consultation time poses a substantial burden to continued attendance, especially when recurrent over the numerous appointments necessary for a patient on ART.  Several studies elsewhere in sub-Saharan Africa have also identified this factor, with one study in Tanzania reporting similar waiting times for ARV users (Hardon et al. 2006).  When added to travel time, it is not hard to see how a visit to the clinic can take an entire day.  Stacked against other regular responsibilities, such as child care and employment, this time constraint is a serious challenge to maintaining ART. 

Staffing Limitations
	In addition to the lack of physical infrastructure necessary for ART, the personnel needed to fully staff and operate these facilities are not available.  Although considerably less than the 57.3% reported in 2001, the vacancy percentage for medical professionals in South Africa was still 29% in 2006 (Health Systems Trust 2006).  In a recent review of South Africa’s HIV/AIDS policy, Anthony Butler states, “The most important institutional constraint confronting South African policy-makers was a dramatic and worsening shortage of human resources in the public health sector, a shortfall that has been the Achilles’ heel of the biomedical paradigm” (Butler 2005).  Operating with only two-thirds the necessary staff, it is no wonder that ART can not be effectively provided to a larger population.  
Not only does this human resources insufficiency decrease expansion of ART, it reduces both the quality and quantity of time spent with each patient.  Staffing shortages cripple a facility’s ability to provide psychosocial support and follow-up programs that are essential to adherence.  Pre-counseling and supportive adherence counseling have are potent facilitators of adherence, but personnel shortages make these programs impractical.  Furthermore, insufficient human resources place more stress on the few staff available, causing fatigue and a decrease in motivation (Schneider et al. 2006).
The human resource model adopted by the Operational Plan estimates that, “one doctor, two professional nurses, one pharmacist and a dietician are optimal for treating and managing 500 patients” (Stewart and Loveday 2005). While the intentions of the new public health legislation are good, given the disconnect between the massive and growing demand for ART and the scarcity of healthcare professionals and unsatisfactory training programs, it is unlikely that South Africa will be able to meet these requirements in the near future. Moreover, as healthcare workers succumb to HIV/AIDS themselves, the already insufficient human resources will be further depleted by the epidemic they are charged to fight.  If there are not enough medical professionals, ART access cannot expand and the small proportion patients on ART will not be properly cared for and supported.

Medication Supply
	Perhaps the most obvious and direct factor affecting adherence is the stability of the supply of ARVs.  Without the consistent provision of medication, patients cannot be expected to stick to their regimen schedule.  The ARVs for many of the non-governmental organizations (NGO) that provide ART are donated, which can cause erratic supply levels as well as frequent changes in regimens based on what drugs are available.  Even in public facilities supply interruptions have occurred due to bureaucratic delays in  paying the suppliers (Stewart and Loveday 2005).  No matter what the other conditions, optimal adherence cannot happen without an unwavering supply of medication upstream of the ART sites.
	Not only is the stable medication supply for the individual a concern, but the overall scarcity of these life-saving drugs presents a dilemma for those lucky enough to receive treatment.  When a loved one is HIV-positive but is not yet receiving ARVs, the patient on ART may be tempted to share his or her drugs.  This creates a situation in which now two patients are at low levels of adherence.  If there is an inadequate supply of medication to treat HIV/AIDS—for either the individual or community—adherence will suffer.

Disability Grants
	Legislation determining the distribution of treatment and assistance services is as important to patterns of adherence as the drugs themselves.  According to the guidelines set by the South African Department of Health, only patients with a CD4 count <200cells/µL or a WHO Stage IV AIDS-defining illness are eligible for ART (National Department of Health 2004).  These are the same requirements for the disability grant provided by the South African Welfare Department meant to aid those “too ill or incapacitated to work” (Nattrass 2006).  With these guidelines, an estimated 340,000 HIV-positive South Africans qualify for the grant (Nattrass 2006).  At a maximum value of R740 ($115) a month, comparable to a rural farm worke’rs wage, this is a substantial source of income for people who qualify (Bureau of Democracy Human Rights and Labor 2005).
With these strict criteria for the disability grant, a serious dilemma arises due to the effectiveness of ART.  This life-saving treatment has previously been assumed an unambiguous benefit to all those affected by HIV/AIDS.  However, once a patient begins responding to ART, their CD4 count rises and any opportunistic diseases subside, thereby disqualifying them from receiving the disability grant.  With unemployment rates estimated between 28-42%, the grant money is absolutely vital even to those capable of working, because they are usually unable to find a job (Nattrass 2006).  
Given the desperate socio-economic situation of the vast majority of HIV-positive people in developing countries, individuals in this position may be forced to trade their health for income.  According to the economist Nicoli Nattrass, “It is possible that a small but significant portion may opt to discontinue HAART so as to become AIDS-sick again in order to qualify once more for the disability grant—and then once it is reinstated, go back onto treatment” (Nattrass 2006).  As will be discussed later, this shocking scenario exhibits exactly the type of adherence pattern most destructive to the individual’s health and the broader struggle against the HIV/AIDS epidemic.  Nattrass (2006) also reported, “some people become angry when they test negative, saying that they were hoping to get the grant” and even one woman who said, “‘I love this HIV’ because of the grant”.  This glaring example of the appalling effect that flawed public policy and poverty can have on people’s health vividly demonstrates the complexity and severity of matters surrounding ART adherence.

Economic Factors
	As alluded to in the discussion of the disability grant, economic factors play a substantial role in people’s decisions about their health.  The financial burden that accompanies ART presents a huge challenge to anyone who begins treatment.  One survey found that AIDS-affected South African households spent an average of 34% of their income on health-related expenses compared to 4% nationally (Steinberg, Henry and Health Systems 2002).  Paradoxically, the households hardest hit by the epidemic are also the most underserved and resource constrained. 

Medication and Care Costs
	Although South Africa’s recently implemented Operational Plan aims to relieve direct costs by rolling out ART in the public health sector, free ART is not yet a reality for most patients.  The Health Systems Trust estimates that a single comprehensive ART visit costs R160 ($22) excluding ARVs and laboratory costs (Cleary et al. 2005).  An additional R235 ($33) per month is required to purchase the drugs for the first-line treatment regimen.  Given the number of visits necessary for a person on ART and unremitting requirement for drug renewals, these costs present a significant obstacle that many of the organizations currently delivering ART cannot completely cover.  Even for a well-funded, ART-dedicated NGO like Sinikithemba in Durban, patients must contribute a co-payment of R140 ($20) per visit (Sinikithemba 2005).  Only 14% of South Africa’s population is covered by medical insurance (Health Systems Trust 2006).  For uninsured ART patients not receiving ART free of charge through NGOs or research studies, some portion of these costs must lie with the patient.  
	The detriment to ART due to financial constraints is often dramatic.  A report on adherence in South Africa found costs for patients not covered by medical insurance a “major factor that affects adherence” and quoted one patient who said, “‘It can take three months for me before I come back when I don’t have money’” (Hardon et al. 2006 p67).  A three month treatment interruption would severely impair the effectiveness of long-term ART.  Furthermore, a preliminary study on barriers to adherence in South Africa reported that the cost of medication was the primary reason given for missing doses (Brown and Friedland 2004).  A more extensive study in Botswana—South Africa’s northern neighbor—reports, “44% of patients stated that the cost of ARVs directly interfered with their ability to take treatment regularly” (Weiser et al. 2003).  These authors predicted that, if costs were removed as a barrier, adherence would increase from 54% to 74%.  Thus, medication and care costs, even when subsidized, present a significant barrier to adherence.

Additional Expenses
Even if ART is provided completely free of charge, other costs may force patients to choose between treatment and other immediate needs.  Two of the most commonly reported ART-related expenses across sub-Saharan Africa are transportation and additional food requirements.  As detailed above, the distances that patients must travel to reach a facility providing ART are varied and often long.  Many South Africans must rely on mass transit, public and unofficial, in order to reach their destination. The cost of such service ranges widely depending on the total distance traveled, transportation methods available and remoteness of the patient’s residence.  A analysis in Uganda illustrated this burden by quoting a man who said, “Sir, I come from very far. Over fifty kilometers from here. Before I come to the hospital I have to plan the money for journey fare to the clinic.  In fact my extra drugs got finished yesterday” (Hardon et al. 2006 p282).  Without the money to travel to their ART provider, patients will not be adequately monitored by their doctor and therefore less likely to adhere to drug therapy.  Moreover, because so many people rely on informal transit, the reliability and consistency of these modes of transport can pose a problem.  
In addition to taking medication and attending clinic, beginning ART also requires a certain level of nutrition.  Because poverty is such a serious issue in sub-Saharan Africa, many people already struggle to maintain a steady and healthy diet.  Starting ART adds further strain for two reasons; appetite increases as health returns and some medications are affected by a patient’s food intake.  One woman participating in a study in South Africa stated, “‘If we have no money to buy food, then this medicine is a problem’” (Hardon et al. 2006 p67).  Almost half of AIDS-affected households have insufficient food at times (Steinberg, Henry and Health Systems 2002).  As the body regains strength and weight with the initiation of ART, caloric requirements swell and severely resource-limited individuals may default treatment because they cannot afford the additional food they now need.  
Further complicating the nutrition and treatment relationship, some drugs depend on food schedules which may be erratic for those struggling to get enough to eat.  One patient from a Ugandan study said, “I missed on Sunday because I could not find what to eat and yet had to eat first before taking the tablets” (Hardon et al. 2006) p284).  Understandably, adherence to treatment for a chronic disease takes a backseat when patients lack such a vital necessity as food for themselves or family members.

Balancing Employment with Medical Responsibility
	As mentioned above, a South African patient on ART must make an average of 26.5 visits to his or her clinic annually for appointments with doctors and to refill prescriptions (Cleary et al. 2005).  Combined with the extensive time required for of each visit, ART requires a substantial amount of time spent away from other responsibilities such as employment.  In the unforgiving economic environment of South Africa, the interruption of work is not taken lightly.  With 34% of the population living on less than $2 a day, the most immediate concern for patients who must miss work is the loss of wages (United Nations Development Programme 2006).  Individuals with employment who are still struggling to afford the basic necessities may have to choose between attending clinic and paying rent or feeding their children.  Faced with such a choice, there is little doubt that securing the fundamentals will take precedence over refilling a prescription, and ART adherence will ultimately suffer.
	Furthermore, with unemployment rates estimated between 28-42% most South African’s hesitate to do anything that may cost them their job (Nattrass 2006).  Consistently missing days of work to attend appointments or refill prescriptions will doubtlessly strain an employer-employee relationship.  The South African Constitution contains provisions within the Bill of Rights that protect employees from discrimination and unfair labor practices; more specifically, the Employment Equity Act of 1998 was the first legislation to directly address HIV/AIDS discrimination within the workplace (Whiteside and Sunter 2000).  Despite the good intent of national legislation, HIV/AIDS discrimination is still a reality in South Africa and may cause employees to conceal their HIV status.  In Botswana, a study reported, “32% of patients feared that they could lose their job if they divulged their status at work” (Weiser et al. 2003). If ART patients fear discrimination from their employer and do not disclose their status, it makes it difficult for them to get time off work to attend clinic, negatively impacting adherence.
	The South African economy is unique in the degree with which it depends on migrant labor.  Due to South Africa’s wealth of mineral resources and multiple seaports that serve a large sector of sub-Saharan Africa, mining and trucking are especially prevalent examples of this mobile economy.  Migrant employees, primarily men, often move between homes in rural communities to the urban centers of industry for work.  Between the many necessary appointments for treatment and the demanding drug schedules, being away from their ART provider impairs a patient’s ability to adhere.  Additionally, the high unemployment rates force people to travel in search of work.  A study on adherence in a large township outside Johannesburg wrote, “The main reason reported for missing antiretroviral doses in our study was being away from home, not surprising in a place like Soweto with a high unemployment rate (41%) and where patients must be away from home to look for jobs” (Nachega et al. 2004). This unstable life makes the strict schedules of ART difficult to maintain.  

Social and Cultural Factors
	Gill et al. (2005) introduced their paper warning against complacency about ART adherence in sub-Saharan Africa with, “[E]ven if all structural barriers to HAART are removed, HAART programs can still fail if they do not adequately address behavioral factors influencing adherence.”  In a country as culturally diverse as South Africa, these behavioral factors can be numerous and span a wide spectrum.  When regarding a patient-dependent aspect of treatment, such as adherence, it is critical to consider the social environment and cultural mindset.

Treatment Misconceptions
	The majority of current educational programs in South Africa focus on prevention strategies in order to encourage safer sex practices and decrease transmission of HIV.  Information about disease progression and treatment are less prevalent in these initiatives.  The affect of this disparity was confirmed by a study investigating the knowledge, attitudes, beliefs and practices about ART in Soweto, South Africa.  The investigators found a lower composite score for ART knowledge than general HIV/AIDS knowledge (Nachega et al. 2005).  Of particular significance, the study reported, “sizable minorities believed that ART could cure HIV (49%) and that ART would not cause side effects (36%)” (Nachega et al. 2005).  These misconceptions could be detrimental to the durability of adherence.  As will be discussed later, side effects of ART can be serious and their initiation may cause the abandonment of ART if patients are not adequately prepared to cope.  The notion that ART can cure HIV is even more dangerous.  A respondent to a study in Botswana stated, “‘One of the patients stopped the medicines because he was told that his viral load was undetectable, so he stopped taking his pills because he though he was cured’” (Hardon et al. 2006) p116).  This complete cessation of ART due to a misconception about the nature of the disease and treatment highlights how educational shortcomings compromise adherence.




	The intense cultural stigma surrounding HIV/AIDS is shown by this story, “‘I went inside the house and spent half an hour with those [AIDS-orphaned] children.  When I came out nobody wanted to come near me,’ he said. Mandela said the crowd were singing songs about him outside when he came out of the house, but when he attempted to approach them, they all kept their distance” (Ashforth 2005 p154).  Arguably one of the worldwide heroes of the last century, Nelson Mandela is even more revered in the country that he freed from apartheid.  If fellow South Africans shy away from the opportunity to meet a national legend, clearly the stigma surrounding HIV/AIDS is a powerful and resilient cultural force.  An ART patient voices his concerns about stigma and its affects on disclosure when he states, “If I disclose I will be stigmatized.  They look at us as if we were prostitutes.  We are treated like leprosy patients” (Hardon et al. 2006) p199).  Fears about stigma and discrimination, even from those closest to the patient, strongly affect an individual’s decisions to disclose their HIV status.  
Keeping such a life-altering development secret presents a heavy burden to patients.  They are forced to conceal the many changes in their lives that result from initiating ART, including hiding their drugs and lying about their clinic appointments.  Also, as is discussed below, failure to disclose potentially deprives patients of valuable social support.  A respondent to a study in Soweto, South Africa illustrates these effects saying, 
‘We had a client who say, ‘I can’t tell my mother because she drinks. And when she is drunk, she is going to scorn me.  And she is going to spread rumors about me.’ So if they cannot disclose to members of the family, then they cannot be seen taking their medication.  Obviously, they’ve got to hide to take their medication…and that is going to impact negatively on the adherence.’ (Nachega et al. 2006b).  

This healthcare professional acknowledges the powerful influence that disclosure to family can have on a patient’s ability to consistently take their medication.  In a quantitative study on adherence among the same population, Nachega et al. (2004)  found that “fear of being stigmatized by sexual partners was independently associated with lower adherence”.  This finding highlights disclosure, specifically to sexual partners, as a strong factor in overall adherence rate.  Ultimately, the extra pressure of hiding their HIV status from those closest to them, combined with already strenuous task of maintaining ART, negatively impacts a patient’s ability to effectively manage their disease and adhere to their medication regimen.  

Benefits of Social Support
	ART requires life-long dedication to a healthy lifestyle, medical care and complex drug schedule—a responsibility that no one should have to endure alone.  Once a patient discloses his or her HIV status to at least one person, not only does the patient relieve the burden of hiding their condition, the patient possibly gains a supporter to help manage their disease.  A social supporter assists in two ways, reminding the patient to take medication and encouraging him or her psychologically.  As one medical professional put it, “‘[treatment supporters] are not a doctor or a nurse, they support, they make sure they take their pills, when [the patient] is confused, they count the pills for them’” (Nachega et al. 2006b).  Similarly, a woman on ART relates the strategy of her supporter, “‘My brother helps me in taking my medications by calling me through my mobile phone on the times my medication is due’” (Nachega et al. 2006b).  A social supporter shares some of the responsibility associated with ART, thereby relieving some of the patient’s burden.  Simply learning about the disease and treatment and reminding the patient to take the pills, social supporters have a tremendous impact on a patient’s ability to adhere.
Although a less direct facilitator to adherence, the emotional aid that a social supporter provides is also vital.  As the patient shifts from the early stages of ART concentrated on survival and begins to regain health and a normal lifestyle, sustaining adherence requires psychological endurance.  To maintain successful ART for the long-term, empowered living must become a focus for the patient and social support is essential to this transition of attitude.  For a patient who lacks social support because he or she does not disclose or they are discriminated against, ART becomes a much greater burden and adherence may decline.

Contradictions in Public Leadership
In addition to support on the personal level, it is crucial that the public role-models and political leaders encourage the attitudes and behaviors necessary for adherence to ART.  For the most part, this is not the case in South Africa.  The government’s response to HIV/AIDS has long been controversial because the top politicians have continually resisted Western-based attitudes about the epidemic.  Since he took office, replacing Nelson Mandela, President Thabo Mbeki has denied the connection between HIV and AIDS.  Addressing Parliament, he stated, “A virus cannot cause a syndrome” (Horton 2000).  In response to this mentality, over 5000 scientists signed a document, called the Durban Declaration, affirming the causal relationship between HIV and AIDS (Sidley 2000).  In response, a spokesperson for President Mbeki said that the document would quickly find its way into “the dustbins of the office” (Specter 2007).  Still today, Mbeki has refused to consent to the accepted view that HIV causes AIDS and “has never disavowed the view that H.I.V. medicines are Western inventions aimed at maiming Africans” (Specter 2007).  From the leader of the country hardest hit by the HIV/AIDS pandemic, these sentiments are appallingly detrimental to any educational campaign about ART.  
Regretfully, this outlook on HIV/AIDS does not end with the president; the Minister of Health, Dr. Manto Tshabalala-Msimang, has expressed analogous views.  She referred to the Durban Declaration as an “elitist document” (Specter 2007).  At the 2004 International AIDS Conference in Toronto, Tshabalala-Msimang presented a public health strategy to combat the HIV/AIDS epidemic in South Africa that was centered on the use of garlic, beetroot, and African potato.  Even after the Department of Health employed the Operational Plan to roll out ART in public facilities, she advocated the use of African remedies over ARVs, insisting that these proven drugs were “damaging”, “toxic” and “poisonous” (Specter 2007).  Furthermore, the deputy-president Jacob Zuma was recently put on trial for raping a woman.  Zuma admitted he knew she was HIV-positive, but when asked about his fear of contracting the virus he replied that he had taken a shower to reduce the risk of transmission.  This sort of negligence and ignorance regarding a public health crisis from a beloved leader in South Africa is a slap in the face to any organization struggling to spread HIV/AIDS education or encourage conscientious health choices.
These attitudes and behaviors from government officials carry serious implications for the success of any campaigns aimed at combating HIV/AIDS or supporting proper treatment conduct.  When such irresponsible actions and erroneous beliefs are sanctioned by political leaders, it is no wonder that South Africans are confused about what to believe about HIV/AIDS.  Misconceptions about the disease and treatment will doubtlessly deter patients from fully adhering to their western-based ART, especially when the contradictions come from heroes born of the apartheid struggle.  

Cultural Discord in Care
Cultural factors compromising adherence to ART do not end with the influence of South African figureheads; there are also deeply embedded beliefs that can deter a patient’s inclination for ART.  The dichotomy between western and traditional African healthcare methods makes medical practice in sub-Saharan Africa distinctively challenging.  Frequently, doctors find themselves fighting for ground against the popularized remedies of traditional healers.  Although the two medical philosophies are not always mutually exclusive, there can be serious interactions between conventional and traditional therapies and conflicting notions can negatively impact adherence to prescribed regimens.  
The majority of currently utilized HIV/AIDS medications, healthcare models and prevention and treatment strategies were first cultivated in a western, developed country setting.  According to researcher Suzette Heald, 
The acceptance of biomedical models of the disease has been so much to the forefront that other understandings have been subdued…as the product of ignorance or of outmoded traditional views by those primarily involved in the AIDS field, both by government personnel and Western AIDS specialists.  The language of AIDS is the language of Western science and policy.  All programmes in Africa, whether medical or social have been dominated by the WHO, and more recently UNAIDS, as well as USAID and other Western-based NGOs (Walker et al. 2004 p91).

This external, often white, domination of ART provision creates a racial and cultural divide since the vast majority of the HIV-positive population in South Africa is black.   Cross-cultural communication about healthcare concepts is notoriously difficult, but it becomes even more challenging with ART because it is so convoluted by speculation and stigma.  Furthermore, the South Africans who solely speak their native language may not be able to effectively communicate with foreign, English-speaking medical providers. This language barrier raises concerns about the accuracy of patients’ histories, how well directions can be followed when given in another language, and the doctors’ capabilities to fully address the patients’ problems or questions.  With impaired communication and insufficient cultural understanding between patient and provider, instructions about ART may be misunderstood and any obstacles affecting adherence may not be appropriately addressed.
Not only do externally-sponsored organizations struggle to effectively provide culturally-sensitive healthcare for ART patients, but they must compete with a much more widespread and established system.  In a paper investigating the responses to the introduction of ART in South Africa, Chopra et al. (2006) states, “Antiretroviral therapies are being introduced into a complex HIV treatment environment where they are competing with a multitude of alternative treatments”.  These alternative, or traditional African, therapies are provided by traditional healers who are ubiquitous throughout sub-Saharan Africa and outnumber biomedical health professionals by a hundred-fold or more (Homsy et al. 2004).  In South Africa alone there are reportedly over 350,000 traditional practitioners who serve 60-80% of the population in their communities (Ashforth 2005).  These traditional healers are fully integrated into the societies that are hardest hit by the HIV/AIDS epidemic and can be the most difficult for western-based organizations to access.  
In his book, Witchcraft, Violence, and Democracy in South Africa, Adam Ashforth writes, “In the era of AIDS, business for healers is booming” (Ashforth 2005) p54).  Although subtle, Ashforth’s word choice makes the important distinction that traditional medicine is in fact a business.  As with any profitable practice, traditional healers place substantial effort in the advertisement of their products and services.  A South African study comparing the marketing and legitimization of ART versus alternative medicines attributed the widespread legitimization of traditional medicine to the possible financial reward (Chopra et al. 2006).  The authors cited one respondent who said, “‘He knew a traditional healer that healed his friend. His friend paid R10,000 for the whole treatment. He was the richest traditional healer in X because he had a jet first time in the history of traditional healers’” (Chopra et al. 2006).  The profit potential from exploiting the thousands of desperate HIV-positive individuals in South Africa warrants a certain level of skepticism when regarding traditional medicine.  The successful promotion of traditional therapies was illustrated when Chopra et al. (2006) found “Respondents across all three sites had more detailed knowledge of the indications, effects and how to access these alternative treatments than they did of antiretroviral drugs.”  The imbalance between knowledge of ARVs and alternative therapies, even among individuals already on ART, highlights the strong influence that traditional medicine holds on a large proportion of South Africans.  
Not only does traditional medicine’s competition with Western medicine detract from the initiation of ART, conflicting messages can negatively impact a patient’s adherence.  When ART patients are inundated with inconsistent stances about HIV/AIDS and its treatment, including unfounded claims of cures, they may be tempted to stray from the treatment regimen stipulated by their doctor.  A recent study in Uganda found that, “Use of a traditional medical healer made patients twice as likely to give up on the [ARV] drugs, which can add years to a patient’s life” (IRIN 2007).  Assuming that this preliminary finding is applicable to other cohorts of ART patients in sub-Saharan Africa, the conflicting influence from traditional healers could be a major cause of poor adherence.
Even if HIV-positive individuals remain faithful to ART while simultaneously consulting a traditional healer and accepting alternative therapies, there can be negative consequences on the patient’s ART.  While the majority of the ingested remedies provided by traditional healers have not been tested or researched in any formal way, there are several examples of adverse reactions between common substances and ARVs.  Both garlic and St. John’s Wort have been shown to react with certain ARVs, in some cases reducing the blood concentration of the drug by 57% (Nyika 2007).  This interaction effectively reduces the blood concentration of a perfectly adherent patient to a level equal to a patient taking only half their medication.  Although not yet demonstrated, similarly harmful interference could take place in patients using traditional remedies while on ART.  

Disease and Treatment Factors
	Negative physiological reactions are not solely a concern when the therapies of separate health paradigms clash.  Even within Western medicine there are adherence affecting factors, outside the patient’s control, related to HIV/AIDS and its treatment.  These issues develop from the nature of the disease itself, the possible side effects from the ARVs and the complexity of the prescribed regimen.  In resource-constrained environments, common in sub-Saharan Africa, these difficulties are often exaggerated due to the previously addressed societal conditions that restrict the systems of support and the customization of treatment.

Asymptomatic Nature of HIV/AIDS 
	HIV/AIDS is unique in many aspects, one of which is the extended period of time between initial infection and the symptomatic stages which can last between 10-12 years on average.  Even before an HIV-positive individual shows outward signs of the disease, HIV exploits the immune system severely impairing the person’s ability to defend against other pathogens.  In an effort to avoid this morbid outcome, ART may be initiated when the CD4 count drops below 200 cells/µL even if the patient does not have an AIDS-defining illness.  Under these circumstances, the patient begins therapy before they have experienced the detriment that HIV/AIDS inflicts upon the lives of those it infects. Without proper education, patients weighing the burden of maintaining ART against the perceived consequences of defaulting, may underestimate the importance of adherence if they have not become seriously ill due to HIV/AIDS.

Side Effects 
	The toxicity of ARVs compare to that of chemotherapy agents used in the treatment of cancer.  The possible side effects of these medications are numerous, usually specific to a certain drug, and often severe.  The spectrum of adverse drug reactions includes most commonly: headache, nausea, rash and peripheral neuropathy; and most seriously: lactic acidosis, hepatomegaly, central nervous effects, and intracranial hemorrhage (Max and Sherer 2000).  Such negative physiological reactions are a substantial concern for those on ART.  As to be expected, literature maintains “that the best adherence is seen when medications remove symptoms, whereas adherence is adversely affected if medications produce side effects” (Chesney et al. 1999).  Unfortunately, the treatments for HIV/AIDS fall under the latter category for the majority of patients.
	The concern that the side effects generate is shown by a Ugandan ARV user who states, “‘I only fear the side-effects of the life-saving drug. I fear it will kill us instead of the HIV’” (Hardon et al. 2006) p289).  For those patients not well-informed or distrusting of their care provider, adverse drug reactions and the burden of continued adherence may outweigh the threat of a long-term disease and lead to the abandonment of ART.  Even if patients remain faithful to their treatment, specific side effects may convince them to stray from their schedules.  This type of behavior is exemplified in the testimony of another ART patient who explains, “‘Feeling a lot of heat in the body, especially after taking the drug, and excess sweating makes one embarrassed in public.  So, you feel like postponing the drug to a later time when you are not relating with people’” (Hardon et al. 2006).  As stipulated earlier, irregular adherence can be just as harmful to treatment outcome as poor adherence. 
Assessments of barriers to adherence have highlighted the influence of adverse drug reactions. Nachega et al. (2004) found that concerns about ART side effects among South Africans were associated with lower levels of adherence.  A similar survey in Botswana reported side effects as the fifth most mentioned reason for missing doses (Weiser et al. 2003).  A more in-depth examination of side effects in patients on ART in a developed nation established that “patient-reported symptoms and medication side effects were significantly associated with adherence” (Ammassari et al. 2001).  Ammassari et al. (2001) also found that when experiencing such negative reactions, patients would self-prescribe ‘drug holidays’.  The severity of many side effects diminishes over time, but without proper education and support, patients may discontinue their life-prolonging treatment in favor of more immediate relief.
Also, worthy of consideration is the reduced flexibility of ART in resource-constrained settings like South Africa.  Under ideal conditions, treatment-related factors affecting adherence, like side-effects or regimen complexity, are dealt with by customizing the treatment to fit the patient’s tolerance and lifestyle.  Only three standardized regimens are currently widely available in South Africa, leaving fewer alternatives for any patients suffering from their medications (Stewart and Loveday 2005).

Pill Load, Dosing Frequency and Regimen Complexity
	As established in previous sections, ART presents a tremendous challenge for patients on multiple levels.  But perhaps the most straight-forward burden resulting from the initiation of ART is simply the number of pills a patient must take daily.  A South African patient assigned the first-line regimen of ARVs takes approximately five pills per day, or 150 per month.  Most often, patients must also take preventative antibiotics plus medications for any opportunistic infections they are fighting.  Comprehensive treatment for HIV/AIDS quickly escalates to a responsibility that anyone would struggle to fit into their daily routine.
	In addition to the excessive number of pills required for ART, each medication has specific requirements regarding food or liquid intake and timing.  Many ARVs must be taken on an empty stomach, while others are best absorbed just after a high-fat meal.  Within a single regimen, there may be some drugs that must be taken twice daily while others only once.  These confusing requirements further intensify the challenge of ART and, if not correctly observed, may result in outcomes equal to or worse than not taking the drugs at all.  When faced with the obstacle of complicated regimens, patients may become frustrated or unmotivated to adhere to treatment.
	The affect of regimen complexity on adherence is supported by literature regardless of setting.  In a review investigating patient-reported barriers to ART adherence, Mills et al. (2006a) listed complicated regimens as a significant factor affecting adherence across both developed and developing nations.  Specific to South Africa, two separate studies described the frequency of dosing as a common reason reported by patients for missing doses (Nachega et al. 2004; Orrell et al. 2003).  Moreover, Orrell et al. found that “three times daily treatment was the strongest predictor for both poor adherence and virologic failure” and suggested that “the best improvement in adherence comes with the reduction of dosing frequency” (Orrell et al. 2003).  These conclusions highlight the significance of regimen burden on patients taking ARVs and show how adherence is directly related to the complexity of their treatment.

Poor Adherence Resulting from Barriers to Adherence
The previous sections outlined diverse factors in South Africa that affect a patient’s adherence to ART.  Within each domain of society—be it political, social, cultural or even physiological—there are significant issues that can facilitate or challenge the maintenance of life-prolonging treatment.  Most of the factors previously addressed are beyond the patient’s immediate control.  If the healthcare system serving HIV-positive individuals cannot consistently provide the treatment, care or support needed for successful ART, a patient’s adherence will suffer.  When economic or treatment-related barriers to adherence accumulate beyond a patient’s capacity to cope, they must deviate from their regimen or suspend ART for a period.  Lastly, the social and cultural milieu molds a patient’s knowledge, attitudes and beliefs surrounding their disease and treatment, and when conflicts arise, can adversely affect adherence.  Together, these factors create a complicated and unforgiving environment for patients already struggling to endure a chronic, life-threatening illness.

III. BIOLOGICAL CONSEQUENCES OF POOR ADHERENCE

In an environment as strenuous as that which many HIV-positive individuals must endure, the challenges to ART adherence are numerous and substantial; however the biological consequences of repetitive treatment lapses are equally ominous.  None of the scenarios associated with poor adherence is positive, and they threaten all the previous aid provided to desperate populations.  Social scientists Popp and Fisher (2002) write, 
It can be argued that without very substantial behavioral science-based interventions aimed at ensuring adherence, the seemingly humanitarian efforts of drug companies, governments, and the UN could have explosive unintended negative consequences.  Individual patients may not benefit, may become treatment resistant, and developing countries could become a veritable ‘petri dish’ for new, treatment-resistance HIV strains.
 
The next section will investigate how the previously-discussed societal factors translate into harsh repercussions.  First, it will introduce the biological cascade resulting from incomplete medication compliance. The direct physiological consequences that occur within the individual will then be discussed.  Lastly, the long-term consequence of resistance and its implications for worldwide public health will be examined.

Incomplete Suppression of HIV
	Put simply, drugs don’t work in patients who don’t take them.  As previously established, ARVs operate by impeding specific enzymes that are essential to the replication of HIV.  The most commonly used medications accomplish this by directly interacting with an enzyme inside an infected cell—the place where replication takes place.  Once HIV has been integrated into the host’s DNA, and activated, the cell continuously produces viral proteins.  In order to counteract this incessant threat, the drug concentration within an ART patient must be high enough to ubiquitously interact with and completely inhibits viral replication.  By stopping the HIV life-cycle in its tracks, ARVs successfully limit cellular destruction and the subsequent spread of HIV within the body.  
However, a patient with poor adherence to ART will have decreased or erratic drug concentrations in his or her bodies, leaving openings for HIV to replicate.  If HIV is allowed to multiply unabated, viral load (VL) will rebound.  This inverse relation between adherence levels and virus concentrations has been shown across studies in diverse populations (Bangsberg et al. 2000; Haubrich et al. 1999; Orrell et al. 2003; Paterson et al. 2000). In one of the most in-depth studies, Bangsberg et al. (2000) write, “A strong relationship was found between adherence and concurrent HIV-1 viral load…A decrease of 10% in adherence was associated with a doubling of the HIV RNA level suggesting that small differences in adherence may result in major differences in virologic control.”  The sensitivity of VL to adherence indicates the significance of any barriers to patient’s ability to take their medication.  Furthermore, Nachega et al. (2007) showed that adherence strongly affected the probability of sustaining viral suppression over time.  Biologically, success in the treatment of HIV/AIDS depends largely on the suppression of a patient’s VL because morbidity from immune destruction is directly correlated with the concentration of HIV particles.  As will be discussed below, an increase in VL during treatment is the first step in a series of consequences.  When patients do not take their medication properly, the drugs cannot work to inhibit HIV and reduce the patient’s VL.  This incomplete suppression of HIV in non-adherent patients has several serious implications on both the individual level and eventually for public health as a whole.  

Treatment Failure and Disease Progression
The devious strategy of HIV is that it attacks and incapacitates the very cells that are meant to defend the body from external threats.  When taken correctly, ARVs inhibit HIV replication and allow the restoration of the immune system.  However, patients with poor adherence do not completely suppress HIV.  Consequently, the patient’s CD4 count will decrease as scores of undeterred HIV particles further infect and destroy the immune cells.  Haubrich et al. (1999) verified this outcome and reported a nonlinear relationship between both the CD4 counts and VL related to patient adherence (Figure 1).  Measuring at both month two and six, these investigators showed that patients with lower adherence had both higher VL and lower CD4 than their more adherent counterparts.  The loss of CD4 cells parallels the rise in VL.  Like any classical battle, the outcome depends largely on the number of soldiers on either side.  Poor adherence amplifies the discrepancy between immune cells and viral particles, tipping the scales in favor of HIV.    
 
Source: Haubrich et al. 1999

The CD4 cells are a crucial component of cell-mediated immunity and as their numbers are depleted the whole immune system becomes compromised.  Individuals with weakened defenses are more susceptible to opportunistic infections.  A study by Bangsberg et al. (2001) illustrates the association between poor adherence to ART and the occurrence of opportunistic infections.  They found that none of the participants with greater than 90% adherence had developed an AIDS-related illness compared to 41% in the group with less than 50% adherence.  Because opportunistic infections are usually the direct cause of AIDS death, this dramatic difference between adherence groups illustrates how important adherence is to survival of an HIV-positive patient.  Furthermore, a study in South Africa compared the survival rates of those on ART with their adherence levels and confirmed the correlation between the two (Nachega et al. 2006a).  These researchers state, “patients on HAART claiming <80% of their prescription refills have a risk of mortality that is more than 3 times greater than that of patients who are ≥80% adherent.”  This large difference in mortality between two adherence groups is hard to ignore and illustrates the severity of the adherence issue.
The previous cascade leading from suboptimal drug concentrations to death highlight the most fundamental rationale for encouraging adherence.  If patients do not take their medications, their immune systems will succumb to the inexhaustible pressure of HIV infection.  After the physiological defenses fail, opportunistic infections set in and eventually overwhelm the entire body.  Without proper adherence, the life-prolonging drugs cannot break this cascade and the result is an accelerated demise.

Increased Probability of Transmission
	 Perhaps the most direct, but also most often overlooked, consequence of an increased VL is the increased probability of transmission.  Transmission of HIV occurs through the exchange of bodily fluids that harbor high enough concentrations of the virus, including blood, semen, vaginal secretions and breast milk.  If poor adherence cause VL rebound, then the amount of virus within these fluids will also increase.  Higher concentrations of HIV in bodily fluids results in an increased probability that infection will occur during an exchange.  A study in Thailand investigating transmission of HIV between positive husbands and wives supports the argument that higher VL increases the probability of transmission.  The researchers found that the risk of transmission increased by 81% with every log increment increase in VL (Tovanabutra et al. 2002).  The risk of transmission almost doubles when the VL increases by 10-fold.  Another group found a similar trend in transmission rates from mother to child.  When breast-feeding mothers were prescribed a regimen of ARVs, thereby lowering their VL, vertical transmission was significantly reduced (Volmink et al. 2007).  
This diminished probability of transmission due to ART reveals how, physiologically, treatment is a form of prevention.  This illustrates how poor adherence has substantial implications for widespread public health.  Because the probability of transmission is so dependent on VL, it is absolutely critical that VL be kept as low as possible to discourage the spread of HIV.  Optimal adherence to the prescribed ARV regimen is the best way to maximize the suppression of HIV, keep VL low and reduce transmission.  If optimal adherence is maintained, not only will it be better for the health of the individual, it will decrease the spread of HIV throughout the population.  


The Development of Drug Resistance 
Resistance to ARVs resulting from poor adherence is a more complicated outcome than the previous examples, but the consequences of such a development are severe.  The phenomenon of resistance has received attention recently because it not only threatens the patient in which it develops, but has the potential to undermine our ability to fight the HIV/AIDS pandemic by rendering current treatments ineffective.  While the development of resistance is not unique to HIV, there are certain characteristics of the virus and ART that make HIV particularly prone to becoming resistant.
Like any evolutionary change, the development of resistance first occurs with a mutation—an alteration of the genetic makeup responsible for the overall structure or function of an organism or virus.  As detailed earlier, there are two strands of RNA in every HIV; each strand is converted to DNA then back to RNA before it is incorporated into the newly produced particle.  Experts estimate that a mutation occurs in the HIV genome once every time it is replicated (Weeks and Alcamo 2006) p.218).  This is much higher than in our own cells because viral enzymes lack the proof-reading mechanisms that mammalian cells possess.  So, in just a single HIV replication cycle, there are four possible mutation events; multiply that by the billions of viruses produced daily in an infection individual and the mutation rate reaches astronomical levels.  
Not all mutations are beneficia; most either have no effect or are detrimental to the virus in some way.  Occasionally though, a genetic mutation alters an HIV particle that makes it impervious to a an ARV drug.  Usually the mutant HIV particle is in some way less operational than the standard, or wild-type, strain.  However, when the second ingredient for evolution, selection pressure, is added, the mutant may gain the advantage.  Selection pressure occurs when ARVs incapacitate the wild-type strain, but are ineffective against the mutant strain.  Now the few resistant HIV particles do not have to compete with the more efficient wild-type strain and the resistant strain is able to expand and dominate the HIV population.  
It is a common belief among biologists and medical professionals that non-adherence to medication breeds drug-resistance.  However, with this evolutionary model of resistance in mind, one can see that the connection between adherence and resistance is much more complicated.  To begin with, the relationship is not simply linear but more ‘u-shaped’ (Figure 2).  Under circumstances of optimal adherence, viral replication is essentially blocked.  Therefore, it is true that at the highest levels of adherence the threat of resistance is lowest because mutations cannot occur without replication.  A review of studies addressing the adherence and resistance relationship reported, “the likelihood of accumulating new mutations will increase sharply with even small departures from perfect adherence, with a rise to 1.9 times higher with individuals with 90% adherence” (Braithwaite et al. 2006).  While exceptional adherence effectively prevents resistance by stopping viral replication, this optimal range is a narrow one.  
Conversely, because most mutant strains are less effective virulent than the wild-type strains, a certain level of selection pressure is required before the mutant strains are able to out-compete the wild-type strains.  Low levels of adherence do not impose the necessary selection pressure on the HIV population so mutant strains do not persist and resistance is less likely to arise (Bangsberg et al. 2003).  This ‘u-shaped’ pattern leaves the moderately adherent patients on ART at the greatest risk for the development of resistance (Braithwaite et al. 2006). 


This issue is further complicated because the adherence and resistance relationship differs depending on the ARV drug class.  NNRTI-based drug regimens are more likely to produce resistance compared to PI-based because of several factors.  Firstly, the NNRTIs act on RT at an area separate from the active site—the location required for enzymatic activity—so changes at this position do not have as large an effect on RT’s overall function.  Also, the high potency and extended half-life of NNRTIs increase both the magnitude and duration of selection pressure and therefore promote greater resistance development under conditions of poor adherence (Bangsberg et al. 2004).  These characteristics of NNRTIs cause the threat of resistance to be highest at low adherence for this class, unlike the ‘u-shaped’ model because even the lowest concentrations of NNRTIs create enough selection pressure to affect HIV.  In contrast to NNRTIs, PIs and NRTIs require multiple mutations in their enzyme before the drug becomes ineffective.  In addition, each of these changes alters enzyme function, possibly making it less virulent (Clotet 2004).  Given these reasons, it is not surprising that NNRTI resistance is seen more often than PI or NRTI resistance.  
No matter what the regimen, resistance is most likely to develop in patients with substantial selection pressure from ARV medications but partial suppression of viral replication, a direct result of sub-optimal adherence.  This balance between VL and selection pressure from medications has other contributing factors—including immune strength, co-infections and baseline mutations—which further complicate the connection between adherence and resistance.  Although the majority of studies have shown that, above the average levels, increased adherence is beneficial in preventing drug resistance, Bangsberg et al. (2003) has shown that perfect adherence may not completely prevent the development of resistance and, in some cases, poorer adherence may actually relieve the selection pressure which breeds resistance.  Nevertheless, as this paper has discussed in detail, there are many benefits of optimal adherence—such as decreased transmission probability and a patient’s clinical outcome—that outweigh any hesitation to adhere to the prescribed ARV regimen because of resistance concerns.  
Even though resistance should not affect a patient’s behavior regarding their HIV medication, it has serious consequences for the individual.  Once a mutation occurs that allows HIV to escape the effects of an ARV drug, it can continue to replicate and spread throughout the system unabated.  Eventually the VL rebounds despite the presence of appropriate medication concentrations and the mutant strain dominates the HIV population.  Once the majority of the virus becomes insusceptible to a specific drug, the drug becomes useless and the disease will progress if nothing is changed.  In order to combat disease progression due to resistance, the patient’s medication regimen must be revised so that the ineffective drug is replaced.  
In developed countries, the medical provider can tailor a patient’s regimen to his or her specific resistance profile.  However, in resource-constrained settings, the healthcare system lacks this flexibility.  When a South African patient dependent on public or non-profit services becomes resistant, he or she usually have only the choice of switching between the two separate, predetermined regimens—from a NNRTI-based (first-line regimen) to a PI-based regimen (second-line regimen).  The consequences of this substitution for the individual range from renewed side-effects, incompatibility with other medications, altered food and storage requirements, and a decreased maximum suppression of VL.  If resistance continues to develop and multiple medications are rendered useless, salvage therapy is required.  This entails the use of a fresh set of recently developed medications.  These novel drugs are most often more expensive and usually unavailable to underserved populations, such as the majority of sub-Saharan Africa.  If a patient exhausts their therapeutic options, treatment failure will eventually occur and they will progress to AIDS.
While this outcome is dire, the consequences of drug resistance extend far beyond the individual.  The phenomenon of resistance is not confined to the person in whom the mutation occurred because the drug-resistant HIV can be transmitted to others.  If the mutation of HIV occurs within the person, then their resistance is termed acquired.  Conversely, primary resistance results when a person with acquired resistance transmits the mutant strain (Vella and Palmisano 2005).  Resistance prevalence directly correlates with the degree of ART in a given population.  The Institute of Medicine asserts, “The prevalence of resistance HIV and the level of transmission of drug-resistant strains are a direct function of the number of persons treated and the amount of therapy provided” (Institute of Medicine 2005b).  For example, a US study estimated the resistance prevalence was 48% in 2004 compared to most developing countries whose resistance levels remain below 5% (Vella and Palmisano 2005). The Centers for Disease Control reported more conservative values for the US, but showed that the overall resistance rates had increased from 5.5% in 1998 to 14.5% in 2004 (Waters and Nelson 2007).  This trend is a dangerous one if new ways to combat HIV are not invented.  If resistance continues to develop at this rate, it will undermine our ability to treat HIV/AIDS in a large number of people and ultimately untreatable drug-resistant strains will dominate.  




With the lives of 38.6 million people directly threatened by HIV/AIDS, and countless more adversely affected by the pandemic, treatment of this disease is absolutely imperative.  Due to the unforgiving nature of the virus, ART is complex and requires a high level of diligence and endurance.  If the prescribed treatment is not accurately adhered to, several dire consequences result.  This paper outlined the how poor adherence allows HIV to rebound and overwhelm the immune system.  With these physiological defenses impaired, other pathogens can thrive and cause severe deterioration of the individual’s health, eventually leading to death if left untreated.  In addition to showing how it is a detriment t o the patient, this paper discussed how poor adherence concerns public health.  The decrease in VL due to ART has been proven to lower the probability of transmission—the goal of prevention measures.  Poor adherence negates this preventative effect of ART by allowing the re-escalation of viral concentrations in high-risk bodily-fluids.  Lastly, the development of drug-resistant strains of HIV poses an intense and unrelenting threat to public health worldwide.  Resistance is directly correlated with adherence levels and may be the direst consequence of improper medication compliance because, as access to ART expands in developing countries, much larger populations will be taking the medications that breed resistant HIV.  The concern of resistance developing in any region is concern for the world, because, with in the modern age of travel, people can travel the breadth of the globe in day.  The full impact of the consequences of poor adherence cannot be predicted with any assurance, but in every scenario, the outlook is grave.  For these reasons, special attention must be paid to the challenges affecting ART adherence to insure the best possible outcome for the patient and avoid the deterioration of HIV/AIDS healthcare.  
Adherence to ART is difficult even under the most ideal circumstances; unfortunately, the majority of people infected with HIV live in the most resource-constrained and underserved regions in the world.  Sub-Saharan Africa contains the large majority of HIV-infected people and hosts many challenges to ART.  In particular, the environment confronting most South Africans presents a wide-variety of issues affecting adherence across almost every sector of society.  As this paper discussed, health service factors play a primary role in the maintenance of ART.  Without adequate infrastructure, staffing or public health policies, South African healthcare cannot properly support and encourage adherence.  Economic constraints are particularly relevant in sub-Saharan Africa and contribute to poor adherence if ART-related costs cannot be met.  Similarly, the physiological characteristics of HIV/AIDS and ART can overwhelm a patient, causing them to default on their treatment.  Finally, this paper highlighted how the social and cultural environments influence a patient’s inclination to adhere to ART.  Education about disease and treatment is essential to therapy maintenance, whereas misconceptions and stigma are powerful barriers to ART adherence.  Furthermore, cultural beliefs—expressed by public officials or intimate relations—along with conflicts between Western and traditional medical paradigms significantly impact a patient’s adherence level.
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Fig. 2. Hypothetical Adherence Resistance Curve
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